m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT03154
|
[1] | |||
Histone modification
H3K18la
Epigenetic Regulator
ALKBH5
Direct
Enhancement
m6A modification
NLRP3
NLRP3
ALKBH5
Demethylation
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | RNA demethylase ALKBH5 (ALKBH5) | ERASER | |||
| m6A Target | NACHT, LRR and PYD domains-containing protein 3 (NLRP3) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Histone modification (HistMod) | ||||
| Regulated Target | Histone H3 lysine 18 lactylation (H3K18la) | View Details | |||
| Downstream Gene | ALKBH5 | View Details | |||
| Crosstalk Relationship | Histone modification → m6A | Enhancement | |||
| Crosstalk Mechanism | Histone modification directly impacts m6A modification through modulating the level of m6A regulator | ||||
| Crosstalk Summary | G6PT deficiency induces intracellular lactate accumulation, which enhances histone Histone H3 lysine 18 lactylation (H3K18la) and upregulates ALKBH5 expression; ALKBH5 demethylates m6A modification on NACHT, LRR and PYD domains-containing protein 3 (NLRP3) mRNA, leading to NLRP3 mRNA degradation and diminished inflammasome activation. | ||||
| Cell Process | mRNA stability | ||||
In-vitro Model |
THP-1 | Childhood acute monocytic leukemia | Homo sapiens | CVCL_0006 | |
| Caco-2 | Colon adenocarcinoma | Homo sapiens | CVCL_0025 | ||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| NACHT, LRR and PYD domains-containing protein 3 (NLRP3) | 4 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
 Compound Name |
Dapansutrile | Phase 2 | [2] | |
|---|---|---|---|---|
| Synonyms |
54863-37-5; OLT1177; UNII-2Z03364G96; 2Z03364G96; Dapansutrile [INN]; Dapansutrile [USAN:INN]; Dapansutrile (USAN/INN); 3-Methylsulfonylpropionitrile; 3-methanesulfonylpropanenitrile; 3-methylsulphonyl-propionitrile; SCHEMBL9934796; CHEMBL3989943; LQFRYKBDZNPJSW-UHFFFAOYSA-N; MolPort-008-545-498; ZINC32005410; Propanenitrile, 3-(methylsulfonyl)-; AKOS010140086; D10920; Z2719319073
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| External Link | ||||
| Compound Name |
BMS-986299 | Phase 1 | [3] | |
| MOA | Agonist | |||
| External Link | ||||
| Compound Name |
Selnoflast | Phase 1 | [4] | |
| Synonyms |
1-(1-ethylpiperidin-4-yl)sulfonyl-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea; 1-Ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-4-piperidinesulfonamide; 1-ethyl-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]piperidine-4-sulfonamide; 2260969-36-4; 4-Piperidinesulfonamide, 1-ethyl-N-(((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)amino)carbonyl)-; 4-Piperidinesulfonamide,1-ethyl-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-; CHEMBL5095423; CS-0204138; Example 6 [WO2019008025A1]; GTPL12173; HY-132831; MFCD34579587; MS-26540; RG6418; RG-6418; RO7486967; RO-7486967; SCHEMBL20634304; Selnoflast; Selnoflast [INN]; Selnoflast [USAN:INN]; Selnoflast [USAN]; SY347075; T23RPA8WA2; UNII-T23RPA8WA2; WHO 11687
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| External Link | ||||
| Compound Name |
MCC950 | Investigative | [5] | |
| Synonyms |
210826-40-7; MCC-950; CP-456773; CHEMBL3183703; N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide; MCC 950; DSSTox_RID_82252; DSSTox_CID_27301; DSSTox_GSID_47301; SCHEMBL6521858; GTPL8228; DTXSID2047301; MolPort-042-579-517; EX-A1052; BCP15729; Tox21_300462; BDBM50155926; ZINC34025113; AKOS030238802; SB19010; NCGC00254269-01; NCGC00248064-01; HY-12815; CAS-210826-40-7; 1-[4-(1-Hydroxy-1-methylethyl)-2-furylsulfonyl]-3-[(1,2,3,5,6,7-hexahydro-s-indacene)-4-yl]urea
Click to Show/Hide
|
|||
| MOA | Inhibitor | |||
| Activity | IC50 = 5 nM | |||
| External Link | ||||
References